BR112023025340A2 - Compostos de triptamina fluorada, análogos dos mesmos e métodos usando os mesmos - Google Patents
Compostos de triptamina fluorada, análogos dos mesmos e métodos usando os mesmosInfo
- Publication number
- BR112023025340A2 BR112023025340A2 BR112023025340A BR112023025340A BR112023025340A2 BR 112023025340 A2 BR112023025340 A2 BR 112023025340A2 BR 112023025340 A BR112023025340 A BR 112023025340A BR 112023025340 A BR112023025340 A BR 112023025340A BR 112023025340 A2 BR112023025340 A2 BR 112023025340A2
- Authority
- BR
- Brazil
- Prior art keywords
- fluorinated
- same
- methods
- analogs
- tryptamine compounds
- Prior art date
Links
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical class C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 title abstract 3
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195943P | 2021-06-02 | 2021-06-02 | |
| US202163288313P | 2021-12-10 | 2021-12-10 | |
| PCT/US2022/032000 WO2022256554A1 (en) | 2021-06-02 | 2022-06-02 | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025340A2 true BR112023025340A2 (pt) | 2024-02-20 |
Family
ID=84324579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025340A BR112023025340A2 (pt) | 2021-06-02 | 2022-06-02 | Compostos de triptamina fluorada, análogos dos mesmos e métodos usando os mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240286998A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347559A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523822A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240017363A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022287013A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025340A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3220850A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023018652A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308944A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014437A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022256554A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002557A (es) * | 2020-09-01 | 2023-05-29 | Enveric Biosciences Canada Inc | Derivados de psilocibina halogenada y metodos de uso. |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| WO2023147424A1 (en) * | 2022-01-27 | 2023-08-03 | Terran Biosciences, Inc. | Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine |
| US12157722B1 (en) * | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0848706B1 (en) * | 1995-06-06 | 2003-02-05 | Schering Corporation | Substituted benzene-fused heterocyclics as neurokinin antagonists |
| DE19615232A1 (de) * | 1996-04-18 | 1997-10-23 | Merck Patent Gmbh | Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| US6800637B2 (en) * | 2002-09-12 | 2004-10-05 | Wyeth | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines |
| JP7273731B2 (ja) * | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
| WO2019222552A1 (en) * | 2018-05-16 | 2019-11-21 | University Of Florida Research Foundation | Methods and compositions for substituted 2,5-diketopiperazine analogs |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| MX2023002557A (es) * | 2020-09-01 | 2023-05-29 | Enveric Biosciences Canada Inc | Derivados de psilocibina halogenada y metodos de uso. |
| CA3192617A1 (en) * | 2020-09-20 | 2022-03-24 | Matthew BAGGOTT | Advantageous tryptamine compositions for mental disorders or enhancement |
| US20240051978A1 (en) * | 2020-12-07 | 2024-02-15 | Mindset Pharma Inc. | 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders |
-
2022
- 2022-06-02 KR KR1020237044652A patent/KR20240017363A/ko active Pending
- 2022-06-02 MX MX2023014437A patent/MX2023014437A/es unknown
- 2022-06-02 CA CA3220850A patent/CA3220850A1/en active Pending
- 2022-06-02 AU AU2022287013A patent/AU2022287013A1/en active Pending
- 2022-06-02 EP EP22816868.8A patent/EP4347559A4/en active Pending
- 2022-06-02 IL IL308944A patent/IL308944A/en unknown
- 2022-06-02 US US18/565,565 patent/US20240286998A1/en active Pending
- 2022-06-02 WO PCT/US2022/032000 patent/WO2022256554A1/en not_active Ceased
- 2022-06-02 JP JP2023574858A patent/JP2024523822A/ja active Pending
- 2022-06-02 BR BR112023025340A patent/BR112023025340A2/pt unknown
-
2023
- 2023-12-29 CO CONC2023/0018652A patent/CO2023018652A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL308944A (en) | 2024-01-01 |
| JP2024523822A (ja) | 2024-07-02 |
| CO2023018652A2 (es) | 2024-01-25 |
| MX2023014437A (es) | 2024-03-08 |
| US20240286998A1 (en) | 2024-08-29 |
| EP4347559A1 (en) | 2024-04-10 |
| CA3220850A1 (en) | 2022-12-08 |
| EP4347559A4 (en) | 2025-04-09 |
| AU2022287013A1 (en) | 2023-12-07 |
| KR20240017363A (ko) | 2024-02-07 |
| WO2022256554A1 (en) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014437A (es) | Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos. | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| MX2022005380A (es) | Composiciones que comprenden colina. | |
| CO2018003168A2 (es) | Moduladores de la expresión de kras | |
| MX381069B (es) | Profármacos de carbidopa y l-dopa y métodos de uso. | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| BR112018070852A2 (pt) | composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas | |
| BR112017028194A2 (pt) | moduladores de diaciglicerol aciltransferase 2 (dgat2) | |
| EA201890454A1 (ru) | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| EA202092750A1 (ru) | Соединения ингибиторы vmat2, композиции и способы, относящиеся к ним | |
| BR112018006445A2 (pt) | métodos para tratar distrofia muscular | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| CO2020008769A2 (es) | Moduladores de la expresión dnm2 | |
| MX2019011867A (es) | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. | |
| BR112017007066A2 (pt) | composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade | |
| BR112016012366A8 (pt) | composição não colorante, processo para remodelar as fibras queratínicas e usos da composição | |
| BR112018016198A2 (pt) | compostos antagonistas do receptor de somatostatina e métodos de uso do mesmo | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| BR112019001082A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de uso | |
| BR112022023135A2 (pt) | Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas | |
| BR112018074841A2 (pt) | tablete de bouillon duro |